A Phase 1/2 interventional study of ARO-HBV and Sterile Normal Saline (0.9% NaCl) in Hepatitis B, sponsored by Arrowhead Pharmaceuticals. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-22.
Sponsored by Arrowhead Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Hepatitis B with a site in Australia — 6 open to participants now, 9 under way, none of them phase 3. Hepatitis B · Australia.
Among the 50 studies in Hepatitis B with a site in Australia, this one is the 21st largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 1/2, and was the 29th registered.
1,047 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.
Browse Hepatitis B studies →6 of the 50 studies in Hepatitis B with a site in Australia are open now. Recruiting first, the newest first:
bioLytical Laboratories · Sites in Australia
Ages 18+ · Healthy volunteers
AusperBio Therapeutics Inc. · Sites in Australia, China, Japan and 4 more countries
Ages 18–65
GigaGen, Inc. · Sites in Australia, United States, Hong Kong and 2 more countries
Ages 18+
Kirby Institute · Sites in Australia
Ages 18+ · Healthy volunteers
Kirby Institute · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 9 · Phase 4 4
First in 1999; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is below the median of 145 across 757 interventional studies indexed under Hepatitis B.
Median enrollment 103 across the 42 interventional studies, 186 across the 6 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 50 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.
Arrowhead Pharmaceuticals has 8 studies filed under Hepatitis B — fewer than ten, so there is no comparison to draw.
4 of the studies in Hepatitis B with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07569913bioLytical LaboratoriesA Study to Evaluate the Performance, and Usability of TruPlex HIV/HepB/Syphilis Rapid Test | 2027-01-01 |
| NCT07059403Chimivac INCA Study of SN2001 Dose, Safety & Immunogenicity in Healthy Adults | 2027-04 |
| NCT06537414GlaxoSmithKlineA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) | 2027-05-31 |
| NCT06661148Epigenic Therapeutics, IncStudy of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies in Hepatitis B with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criteria for Part B:
Exclusion Criteria:
NOTE: additional inclusion/exclusion criteria may apply, per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of ARO-HBV 35 mg subcutaneous (sc) injection in normal healthy volunteers
Drug: ARO-HBV
Single dose of ARO-HBV 100 mg sc injection in normal healthy volunteers
Drug: ARO-HBV
Single dose of ARO-HBV 200 mg sc injection in normal healthy volunteers
Drug: ARO-HBV
Single dose of ARO-HBV 300 mg sc injection in normal healthy volunteers
Drug: ARO-HBV
Single dose of ARO-HBV 400 mg sc injection in normal healthy volunteers
Drug: ARO-HBV
Sterile normal saline (0.9% NaCl) sc injection in normal healthy volunteers
Other: Sterile Normal Saline (0.9% NaCl)
ARO-HBV 25 mg sc injection every 28 days (Q28D) in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 50 mg sc injection Q28D in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 100 mg sc injection Q28D in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 200 mg sc injection Q28D in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 300 mg sc injection Q28D in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 400 mg sc injection Q28D in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 100 mg sc injection every 14 days (Q14D) in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 100 mg sc injection every 7 days (Q7D) in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 300 mg sc injection Q28D in hepatitis B e antigen positive/treatment naïve (HBeAg+/Trt Naïve) participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 300 mg sc injection Q28D in HBeAg+/nucleotide or nucleoside analog treated (HBeAg+/NUC) participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 200 mg sc injection Q7D in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 300 mg sc injection Q7D in participants with chronic hepatitis B
Drug: ARO-HBV
ARO-HBV 200 mg sc injection Q28D plus JNJ-56136379 250 mg in participants with chronic hepatitis B
Drug: ARO-HBV · Drug: JNJ-56136379
sc injection
sc injection
oral tablets
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Possibly or Probably Related to Treatment
An adverse event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Assessment of causality utilized 3 possible categories: not related, possibly related and probably related.
Time frame: NHV participants: up to Day 29 (± 2 days); CHB participants: Day 113 (± 2 days)
Part A, Pharmacokinetics (PK) of ARO-HBV Analytes: Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Part A, PK of ARO-HBV Analytes : Time to Maximum Plasma Concentration (Tmax)
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24)
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 hours post-dose
Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf)
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Part A, PK of ARO-HBV Analytes: Area Under the Plasma Concentration Versus Time Curve From Zero to the Time of the Last Quantifiable Concentration (AUC0-t)
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Part A, PK of ARO-HBV Analytes: Terminal Elimination Half-Life (t½)
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Part A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-24
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 hours post-dose
Part A, PK of ARO-HBV Analytes: Dose-Normalized AUC0-t
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Part A, PK of ARO-HBV Analytes: Dose-Normalized Cmax
Time frame: Day 1: 0 (pre-dose), 15 minutes, 0.5, 1, 2, 3, 6, 24 & 48 hours post-dose
Change From Baseline in HBV Surface Antigen (HBsAg) From Day 1 Pre-Dose Baseline to Post-Dose Nadir in Participants Chronically Infected With HBV
Time frame: Part B (multiple-ascending dose [MAD] phase) only: up to 113 days
| Milestone | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg | Placebo | ARO-HBV 25 mg, Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 | 4 | 10 | 8 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 4 | 4 | 4 | 12 |
| Completed | 4 | 4 | 4 | 4 | 4 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 4 | 4 | 4 | 4 | 4 | 4 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment. TEAEs were defined as AEs with onset after administration of the study drug, or when a preexisting medical condition increases in severity or frequency after study drug administration. Assessment of causality utilized 3 possible categories: not related, possibly related and probably related.
| Participants | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg | Placebo | ARO-HBV 25 mg Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Possibly Related TEAE | 1 | 1 | 1 | 1 | 1 | 5 | 2 | 2 | 1 | 1 | 5 | 3 | 0 | 2 | 2 | 0 | 0 | 0 | 0 |
| Probably Related TEAE | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 2 | 0 | 0 | 2 | 1 | 0 | 2 | 0 |
| ng/mL | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-73763976 | 160 ± 106 | 536 ± 390 | 1320 ± 331 | 2920 ± 1670 | 4280 ± 1340 |
| Analyte: JNJ-73763924 | 43.0 ± 25.8 | 117 ± 45.2 | 363 ± 89.5 | 827 ± 447 | 1010 ± 398 |
| hours | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-73763976 | 6.00 (6.00 to 6.03) | 6.00 (3.00 to 6.00) | 6.00 (2.00 to 6.00) | 6.03 (2.00 to 6.05) | 6.00 (6.00 to 6.00) |
| Analyte: JNJ-73763924 | 6.00 (2.00 to 6.00) | 6.00 (2.00 to 6.00) | 1.50 (0.500 to 6.00) | 2.02 (1.00 to 3.00) | 6.00 (6.00 to 6.00) |
| h*ng/mL | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-76763976 | 1830 ± 1190 | 5480 ± 2540 | 17800 ± 4180 | 35500 ± 17200 | 44600 ± 15100 |
| Analyte: JNJ-76763924 | 327 ± NA | 1250 ± 330 | 4320 ± 965 | 8140 ± 3160 | 9720 ± 3680 |
| h*ng/mL | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-6763976 | — | 5820 ± NA | 12600 ± NA | 14800 ± NA | — |
| Analyte: JNJ-76763924 | 365 ± NA | 1530 ± NA | 4610 ± 1190 | 8170 ± 3420 | — |
| h*ng/mL | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-76763976 | 1830 ± 1190 | 5740 ± 2480 | 20100 ± 5250 | 37900 ± 16900 | 46900 ± 17400 |
| Analyte: JNJ-76763924 | 254 ± 127 | 1250 ± 330 | 4600 ± 1130 | 8330 ± 2820 | 9940 ± 3990 |
| hours | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-6763976 | — | 6.45 ± NA | 5.83 ± NA | 9.16 ± NA | — |
| Analyte: JNJ-76763924 | 7.52 ± NA | 5.97 ± NA | 6.48 ± 1.23 | 6.02 ± 2.34 | — |
| h*ng/mL/mg | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: NJ-76763976 | 52.1 ± 34.1 | 54.8 ± 25.4 | 88.9 ± 20.9 | 118 ± 57.3 | 111 ± 37.7 |
| Analyte: JNJ-6763924 | 9.34 ± NA | 12.5 ± 3.30 | 21.6 ± 4.83 | 27.1 ± 10.5 | 24.3 ± 9.20 |
| h*ng/mL/mg | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-6763976 | 52.1 ± 34.1 | 57.4 ± 24.8 | 101 ± 26.3 | 126 ± 56.5 | 117 ± 43.5 |
| Analyte:JNJ-76763924 | 7.25 ± 3.63 | 12.5 ± 3.30 | 23.0 ± 5.65 | 27.8 ± 9.39 | 24.8 ± 9.98 |
| ng/mL/mg | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg |
|---|---|---|---|---|---|
| Analyte: JNJ-76763976 | 4.56 ± 3.03 | 5.36 ± 3.90 | 6.58 ± 1.65 | 9.72 ± 5.58 | 10.7 ± 3.34 |
| Analyte: JNJ-76763924 | 1.23 ± 0.737 | 1.17 ± 0.452 | 1.81 ± 0.448 | 2.76 ± 1.49 | 2.53 ± 0.994 |
| IU/mL | ARO-HBV 25 mg Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change From Baseline in HBV Surface Antigen (HBsAg) From Day 1 Pre-Dose Baseline to Post-Dose Nadir in Participants Chronically Infected With HBV | -1.083 ± 0.5320 | -1.199 ± 0.2525 | -1.695 ± 0.4921 | -1.769 ± 0.4018 | -1.534 ± 0.3080 | -1.889 ± 0.6948 | -1.549 ± 0.2956 | -1.412 ± 0.4153 | -2.252 ± 1.0177 | -2.492 ± 0.6493 | -2.316 ± 0.6979 | -1.879 ± 0.2676 | -1.687 ± 0.3887 |
Collected over From the screening period (Day -60) and up to the end of the follow-up of the study (Day 398). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARO-HBV 35 mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| ARO-HBV 100 mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| ARO-HBV 200 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| ARO-HBV 300 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| ARO-HBV 400 mg | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| ARO-HBV 25 mg Q28D | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| ARO-HBV 50 mg Q28D | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| ARO-HBV 100 mg Q28D | 0/8 (0%) | 1/8 (12.5%) | 5/8 (62.5%) |
| ARO-HBV 200 mg Q28D | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| ARO-HBV 300 mg Q28D | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| ARO-HBV 400 mg Q28D | 0/8 (0%) | 1/8 (12.5%) | 7/8 (87.5%) |
| ARO-HBV 100 mg Q14D | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| ARO-HBV 100 mg Q7D | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| ARO-HBV 300 mg, Q28D, HBeAg+/NUC | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| ARO-HBV 200 mg, Q7D | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| ARO-HBV 300 mg, Q7D | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg | 0/12 (0%) | 1/12 (8.3%) | 3/12 (25%) |
| Event | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg | Placebo | ARO-HBV 25 mg Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HyperparathyroidismEndocrine disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/12 |
| AnxietyPsychiatric disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| DepressionPsychiatric disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| MenorrhagiaReproductive system and breast disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| Retroperitoneal massGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/12 |
| Event | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg | Placebo | ARO-HBV 25 mg Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/4 | 1/4 | 0/4 | 0/4 | 1/4 | 2/10 | 1/8 | 3/8 | 0/8 | 3/8 | 2/8 | 4/8 | 1/4 | 1/4 | 1/4 | 1/4 | 3/4 | 0/4 | 2/12 |
| NauseaGastrointestinal disorders | 0/4 | 1/4 | 1/4 | 2/4 | 0/4 | 1/10 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/12 |
| FatigueGeneral disorders | 0/4 | 0/4 | 2/4 | 0/4 | 0/4 | 1/10 | 1/8 | 1/8 | 1/8 | 0/8 | 0/8 | 1/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| HeadacheNervous system disorders | 1/4 | 2/4 | 1/4 | 1/4 | 2/4 | 2/10 | 0/8 | 1/8 | 0/8 | 0/8 | 3/8 | 1/8 | 0/4 | 1/4 | 0/4 | 0/4 | 1/4 | 1/4 | 0/12 |
| Blood creatine phosphokinase increasedInvestigations | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/10 | 1/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/4 | 2/4 | 1/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| Back painMusculoskeletal and connective tissue disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/10 | 0/8 | 1/8 | 0/8 | 0/8 | 1/8 | 0/8 | 0/4 | 2/4 | 1/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| AcneSkin and subcutaneous tissue disorders | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/4 | 0/4 | 2/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/4 | 1/4 | 0/4 | 0/4 | 0/4 | 1/10 | 0/8 | 0/8 | 0/8 | 1/8 | 1/8 | 0/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| Abdominal pain lowerGastrointestinal disorders | 0/4 | 0/4 | 1/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/12 |
| Abdominal pain upperGastrointestinal disorders | 1/4 | 1/4 | 0/4 | 0/4 | 0/4 | 0/10 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 1/8 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/12 |
| Age, Continuous(years) | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg | Placebo | ARO-HBV 25 mg Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 22.0 ± 3.01 | 23.5 ± 0.67 | 24.8 ± 4.23 | 28.1 ± 8.15 | 23.6 ± 3.73 | 27.2 ± 9.08 | 42.8 ± 7.17 | 47.8 ± 6.97 | 50.8 ± 12.48 | 47.5 ± 6.75 | 52.1 ± 7.42 | 41.0 ± 9.91 | 48.9 ± 7.71 | 40.7 ± 6.59 | 31.8 ± 7.90 | 36.0 ± 4.93 | 53.2 ± 6.67 | 50.7 ± 12.39 | 44.9 ± 9.19 | 40.3 ± 12.7 |
| Sex: Female, Male(Participants) | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg | Placebo | ARO-HBV 25 mg Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 3 | 2 | 6 | 3 | 2 | 2 | 3 | 0 | 2 | 1 | 1 | 2 | 2 | 3 | 1 | 4 | 42 |
| Male | 2 | 2 | 3 | 1 | 2 | 4 | 5 | 6 | 6 | 5 | 8 | 6 | 3 | 3 | 2 | 2 | 1 | 3 | 8 | 72 |
| Race (NIH/OMB)(Participants) | ARO-HBV 35 mg | ARO-HBV 100 mg | ARO-HBV 200 mg | ARO-HBV 300 mg | ARO-HBV 400 mg | Placebo | ARO-HBV 25 mg Q28D | ARO-HBV 50 mg Q28D | ARO-HBV 100 mg Q28D | ARO-HBV 200 mg Q28D | ARO-HBV 300 mg Q28D | ARO-HBV 400 mg Q28D | ARO-HBV 100 mg Q14D | ARO-HBV 100 mg Q7D | ARO-HBV 300 mg, Q28D, HBeAg+/Trt Naïve | ARO-HBV 300 mg, Q28D, HBeAg+/NUC | ARO-HBV 200 mg, Q7D | ARO-HBV 300 mg, Q7D | ARO-HBV 200 mg Q28D + JNJ-56136379 250 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 3 | 1 | 0 | 0 | 1 | 6 | 6 | 8 | 8 | 5 | 6 | 3 | 1 | 3 | 4 | 4 | 3 | 12 | 74 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 1 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 13 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| White | 3 | 0 | 3 | 3 | 3 | 8 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Apr 2020, 24 months.
Results were first posted in Jun 2024, 4 years 1 month after primary completion. A results delay was requested in Apr 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.